Fulcrum Therapeutics (FULC) Non-Current Debt (2018 - 2021)

Fulcrum Therapeutics (FULC) has reported Non-Current Debt for 4 consecutive years, with $2.6 million the latest figure, recorded in Q4 2021.

• In Q4 2021, Non-Current Debt fell 15.37% year-over-year to $2.6 million; the TTM figure through Dec 2021 stood at $2.6 million (down 15.37% YoY), while the FY2021 annual figure was $2.6 million, down 15.37% from the prior year.
• Non-Current Debt eased to $2.6 million in Q4 2021 per FULC's latest filing, from $2.7 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $4.0 million in Q4 2018 and bottomed at $2.6 million in Q4 2021.
• Historically, Non-Current Debt has averaged $3.2 million across 4 years, with a median of $3.2 million in 2020.
• Annual changes were most pronounced in 2019 — Non-Current Debt declined 11.75% — and 2021, when it decreased 15.37%.
• Fulcrum Therapeutics' Non-Current Debt stood at $4.0 million in 2018, then dropped by 11.75% to $3.5 million in 2019, then decreased by 13.35% to $3.1 million in 2020, then fell by 15.37% to $2.6 million in 2021.
• Business Quant data shows FULC's Non-Current Debt at $2.6 million in Q4 2021, $2.7 million in Q3 2021, and $2.8 million in Q2 2021.